Article
P226 FRACTION-RCC: a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC.
Journal for ImmunoTherapy of Cancer
Publication/Presentation Date
11-1-2017
Disciplines
Document Type
Article
Citation Information
Taitt, C. C., Motzer, R. J., Choueiri, T. K., Escudier, B. J., Kuzel, T. Carducci, M. A., Nair, S. G. & ... Fracasso, P. M. (2017, November). P226 FRACTION-RCC: a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC. Journal for ImmunoTherapy of Cancer 5 (Suppl 2): 87. https://doi.org/10.1186/s40425-017-0288-4
Was Presented on November 2017 at the 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two in National Harbor, MD.